Drugs / 13-valent conjugate pneumococcal vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01974817 | May → Dec 2013 | end stage renal failure | Michigan State University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-valent conjugate pneumococcal vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01974817 ↗ |
| Known as | PCV13 | “We evaluated the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in this population.” PMID 27581438 ↗ Nov 2016 |
| Route | Intramuscular | “Patients will receive one dose of 0.5ml of Prevnar-13 intra-muscularly.” NCT01974817 ↗ |